Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, October 8, 2026

Back to today

From X

@StableBread

Fajasy on X

How did a boiler maker founded in 1867 become the Navy’s reactor supplier? BWX Technologies’ $BWXT history runs through two spin-offs and a decade of acquisitions: → 1867: George Babcock and Stephen Wilcox found Babcock & Wilcox (B&W) to make steam boilers. → 1953-1955: B&W builds components for the USS Nautilus, the first nuclear-powered submarine. → 1978: J. Ray McDermott, an offshore engineering firm, buys B&W. → 2008: B&W buys Nuclear Fuel Services, the Erwin, Tennessee plant behind the Navy’s fuel. → 2010: B&W spins off from McDermott as a standalone public company. → 2015: B&W spins off its boiler business as Babcock & Wilcox Enterprises $BW and renames itself BWX Technologies, keeping the naval and other nuclear businesses. → 2016-2020: Buys GE Hitachi Nuclear Energy Canada (fuel for CANDU, Canada’s heavy-water reactor design, 2016), Nordion’s medical isotope business (2018), and nuclear parts maker Laker Energy (2020), building out the Canadian commercial business. → 2022: Wins Project Pele, the Pentagon’s prototype transportable microreactor. → 2025: Buys the Aerojet Ordnance Tennessee (A.O.T.) unit of L3Harris $LHX for ~$100M in January and closes the Kinectrics deal (a Toronto-based nuclear engineering and testing firm, ~US$525M including assumed liabilities) in May. → 2026: Closes its purchase of Precision Components Group (PCG), a U.S. maker of heat exchangers and other heavy components, for ~$200M on July 1. Most recently, on August 3, Nordic Capital, a private equity firm, agreed to buy just over 80% of $BWXT’s medical isotope business for $750M plus up to $50M more. $BWXT wasn’t looking to sell until Nordic reached out, CEO Rex Geveden said on the Q2 call the same day. CFO Mike Fitzgerald said on the same call that the medical business should bring in $130M of 2026 revenue, at a margin “modestly accretive” to the 13% $BWXT expects from its commercial segment. Nordic’s $750M for just over 80% implies ~$0.9B for 100%, or ~7x revenue. At a ~14% margin, that’s ~50x EBITDA, more than double the 22.5x EBITDA $BWXT trades at. So $BWXT is selling a small side business at a premium to focus on what it calls its core businesses, nuclear national security and nuclear power.
@leevalueroach 1 click

Lee Roach on X

The CEO of Beasley Broadcasting $BBGI is seen here wearing a $60,000 Van Cleef necklace in her headshot on the company's website. This is the nepo baby that drove her family's business into the ground and then diluted equity holders to all hell with a nasty equity raise. I think she should sell her high end jewelry collection and start using the funds to pay down the company's debt. Still no word on who the entity was who bought into that deal. They now own 25% of the Class A stock and are past the SEC filing deadline. Could it be members of the family getting a sweetheart deal and really screwing minority shareholders here? Asset sales have been nil. Someone check Caroline's Neiman Marcus credit card transactions! Have more Van Cleef's been acquired in the interim?

Investor Letters

All letters

Not So Fast

Entravision, the portfolio’s largest position, fell more than 40% from its highs as Q3 returns dropped to 37.8% YTD.

EVC $634M
The Mikro Kap 1 click
KVHI · long

KVH Industries

KVH Industries is winding down capital-intensive GEO antenna manufacturing and pivoting to an asset-light maritime connectivity business.

KVHI $120M
Value Investors Club 3 clicks

SCIA- SCI Engineered Materials

SCIA generates $28 million of revenue from thin-film materials, with 78% of sales tied to one customer, while expanding into defense…

SCIA $40M
Sylence Capital

ALTO- ALTO ingredients

ALTO Ingredients trades near half of book value after plant upgrades and lower corn prices set up a recovery in crush margins and cash flow.

ALTO $289M
Sylence Capital 1 click

Notes and Updates

ECIP recipient banks could repurchase Treasury preferred shares at steep discounts, potentially lifting book value, while Hawaiian Electric…

UBAB $186M
Exploring with Alluvial Capital

Mereo Biopharma

Mereo Biopharma has two late-stage assets, seeks non-dilutive financing for alvelestat Phase 3 trials, and reports cash runway through 2027.

MREO $56M
Raging Bull Investments

Revisiting An Old Idea

Instil Bio leased its 128,000-square-foot Tarzana life-sciences building to AstraZeneca for 15 years at $7.52 million annual rent,…

TIL $44M
Raging Bull Investments

Publications we follow

Every publication on this site, hand-picked.

109 publications

Newsletters 92

YouTube 4

Blogs 12

Seeking Alpha 46 of 218

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

74 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.